Journal article
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Abstract
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA-16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival …
Authors
Piccirillo MC; Chu Q; Bradbury P; Tu W; Coschi CH; Grosso F; Florescu M; Mencoboni M; Goffin JR; Pagano M
Journal
Journal of Thoracic Oncology, Vol. 18, No. 6, pp. 813–819
Publisher
Elsevier
Publication Date
6 2023
DOI
10.1016/j.jtho.2023.02.003
ISSN
1556-0864